These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 29196484)

  • 21. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial.
    Ducrotte P; Dapoigny M; Bonaz B; Siproudhis L
    Aliment Pharmacol Ther; 2005 Feb; 21(4):435-44. PubMed ID: 15709995
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomised clinical trial: the clinical effects of a novel neurokinin receptor antagonist, DNK333, in women with diarrhoea-predominant irritable bowel syndrome.
    Zakko S; Barton G; Weber E; Dunger-Baldauf C; Rühl A
    Aliment Pharmacol Ther; 2011 Jun; 33(12):1311-21. PubMed ID: 21507028
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-irritable Bowel Syndrome Syrup Improves Constipation-Predominant Irritable Bowel Syndrome: A Randomized, Placebo-Controlled Trial.
    Pazhouh HK; Hosseini SMA; Taghipour A; Hamedi S; Noras M
    Chin J Integr Med; 2020 Oct; 26(10):729-735. PubMed ID: 32623701
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Otilonium bromide in irritable bowel syndrome: a double-blind, placebo-controlled, 15-week study.
    Battaglia G; Morselli-Labate AM; Camarri E; Francavilla A; De Marco F; Mastropaolo G; Naccarato R
    Aliment Pharmacol Ther; 1998 Oct; 12(10):1003-10. PubMed ID: 9798806
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Faecal microbiota transplantation for diarrhoea-predominant irritable bowel syndrome: a double-blind, randomised, placebo-controlled trial.
    Aroniadis OC; Brandt LJ; Oneto C; Feuerstadt P; Sherman A; Wolkoff AW; Kassam Z; Sadovsky RG; Elliott RJ; Budree S; Kim M; Keller MJ
    Lancet Gastroenterol Hepatol; 2019 Sep; 4(9):675-685. PubMed ID: 31326345
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Xiaoyao-san, a traditional Chinese herbal formula, for the treatment of irritable bowel syndrome: A protocol for a systematic review and meta-analysis.
    Lee J; Sung WS; Kim EJ; Kim YW
    Medicine (Baltimore); 2021 Mar; 100(10):e24019. PubMed ID: 33725813
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapist telephone-delivered CBT and web-based CBT compared with treatment as usual in refractory irritable bowel syndrome: the ACTIB three-arm RCT.
    Everitt H; Landau S; Little P; Bishop FL; O'Reilly G; Sibelli A; Holland R; Hughes S; Windgassen S; McCrone P; Goldsmith K; Coleman N; Logan R; Chalder T; Moss-Morris R
    Health Technol Assess; 2019 Apr; 23(17):1-154. PubMed ID: 31042143
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IBS and the role of otilonium bromide.
    Boeckxstaens G; Corazziari ES; Mearin F; Tack J
    Int J Colorectal Dis; 2013 Mar; 28(3):295-304. PubMed ID: 23178991
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of antispasmodics in the treatment of irritable bowel syndrome.
    Annaházi A; Róka R; Rosztóczy A; Wittmann T
    World J Gastroenterol; 2014 May; 20(20):6031-43. PubMed ID: 24876726
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modified Gwakjeongtang for Diarrhea-Predominant Irritable Bowel Syndrome: Study Protocol for a Randomized, Double-Blind, Placebo-Controlled, Pilot Clinical Trial.
    Choi Y; Ha NY; Kim AR; Jeong H; Kwon O; Park KS; Kim J; Kim J; Kim H
    Int J Gen Med; 2024; 17():1545-1556. PubMed ID: 38680195
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of irritable bowel syndrome with diarrhoea using titrated ondansetron (TRITON): study protocol for a randomised controlled trial.
    Gunn D; Fried R; Lalani R; Farrin A; Holloway I; Morris T; Olivier C; Kearns R; Corsetti M; Scott M; Farmer A; Emmanuel A; Whorwell P; Yiannakou Y; Sanders D; Mclaughlin J; Kapur K; Eugenicos M; Akbar A; Trudgill N; Houghton L; Dinning PG; Ford AC; Aziz Q; Spiller R
    Trials; 2019 Aug; 20(1):517. PubMed ID: 31429811
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The use of anti-spasmodics in the treatment of irritable bowel syndrome: focus on otilonium bromide.
    Forte E; Pizzoferrato M; Lopetuso L; Scaldaferri F
    Eur Rev Med Pharmacol Sci; 2012 Jan; 16(1):25-37. PubMed ID: 22338545
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of acupuncture based on acupoint combination theory for irritable bowel syndrome: a study protocol for a multicenter randomized controlled trial.
    Sun JW; Sun ML; Li D; Zhao J; Shi SH; Li HX; Liu HM; Gao JX; Hu Y; Zheng H; Wang X; Xue RD; Feng X; Yu SG; Li ZG
    Trials; 2021 Oct; 22(1):719. PubMed ID: 34666815
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomised clinical trial: pregabalin vs placebo for irritable bowel syndrome.
    Saito YA; Almazar AE; Tilkes KE; Choung RS; Van Norstrand MD; Schleck CD; Zinsmeister AR; Talley NJ
    Aliment Pharmacol Ther; 2019 Feb; 49(4):389-397. PubMed ID: 30663077
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The efficacy of Bifidobacterium quadruple viable tablet in the treatment of diarrhea predominant irritable bowel syndrome: protocol for a randomized, double-blind, placebo-controlled, multicenter trial.
    Bai T; Zeng H; Long Y; Li X; Sun X; Lan Y; Gao L; Zhang L; Feng Z; Hou X
    Trials; 2020 Jun; 21(1):597. PubMed ID: 32605578
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and Safety of Peppermint Oil in a Randomized, Double-Blind Trial of Patients With Irritable Bowel Syndrome.
    Weerts ZZRM; Masclee AAM; Witteman BJM; Clemens CHM; Winkens B; Brouwers JRBJ; Frijlink HW; Muris JWM; De Wit NJ; Essers BAB; Tack J; Snijkers JTW; Bours AMH; de Ruiter-van der Ploeg AS; Jonkers DMAE; Keszthelyi D
    Gastroenterology; 2020 Jan; 158(1):123-136. PubMed ID: 31470006
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of 'Zesy002' kiwifruit (
    Eady SL; Wallace AJ; Butts CA; Hedderley D; Drummond L; Ansell J; Gearry RB
    J Nutr Sci; 2019; 8():e18. PubMed ID: 31080591
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of diarrhea-predominant irritable bowel syndrome with traditional Chinese herbal medicine: a randomized placebo-controlled trial.
    Leung WK; Wu JC; Liang SM; Chan LS; Chan FK; Xie H; Fung SS; Hui AJ; Wong VW; Che CT; Sung JJ
    Am J Gastroenterol; 2006 Jul; 101(7):1574-80. PubMed ID: 16863563
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline.
    Rivkin A; Rybalov S
    Pharmacotherapy; 2016 Mar; 36(3):300-16. PubMed ID: 26971716
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of acupuncture in refractory irritable bowel syndrome: study protocol for a randomised controlled trial.
    Zhao J; Chen M; Wang X; Ye K; Shi S; Li H; Wang J; Chen X; Ni J; Wei Q; Shi Y; Hu Y; Sun J; Li D; Liu S; Li Z; Zheng H; Yu SG
    BMJ Open; 2021 Sep; 11(9):e045655. PubMed ID: 34518248
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.